Bevacizumab, an antibody targeting vascular endothelial growth factor A (VEGF), has been proposed as an active drug, given that glioblastoma is characterized by an abnormal tumor vasculature fueled by pro‐angiogenic stimulation from VEGF overexpression (Baumgarten et al., 2016). This evidence concerns the gene VEGFA and glioblastoma.